Toll-like receptor signaling in sepsis
Related Experiment Video
Updated: Aug 29, 2026

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
Published on: July 26, 2017
Saquib A Lakhani1, Clifford W Bogue
1Section of Pediatric Critical Care, Yale University School of Medicine, New Haven, Connecticut 06520, USA.
Abstract:
Despite extensive research, bacterial sepsis and its associated systemic inflammation remain a major cause of morbidity and mortality in the pediatric intensive care unit. Advances in molecular biology, however, have improved our understanding of this disease process and have opened up new avenues of potential therapeutic approaches. One such exciting area has been the substantial and still growing evidence that the mammalian immune system uses a family of Toll-like receptors (TLRs) to generate a response to molecular patterns present on invading microorganisms. In particular, TLR4 is part of a recognition complex for bacterial lipopolysaccharide (LPS), thus raising the likelihood of its involvement in the inflammatory response to bacterial sepsis. This review highlights our understanding of the molecular biology of these receptors, focusing on the LPS response, and concluding with a summary of ongoing evaluation and potential therapeutic strategies for treating sepsis through blockade of TLR signaling.
Related Concept Videos
Bacterial Signaling
Intracellular Signaling Cascades
Amplifying Signals via Second Messengers
Amplifying Signals via Enzymatic Cascade
The JAK-STAT Signaling Pathway
Acute Inflammation III: Local and Systemic Effects

